Immediate changes in stroke lesion volumes post thrombolysis predict clinical outcome

Stroke

Volumn 45, Issue 11, 2014, Pages 3275-3279

  Luby, Marie ^a   Warach, Steven J ^a,b   Nadareishvili, Zurab ^a,c   Merino, José G ^a,c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Johns Hopkins Community Physicians   (United States)

Author keywords

Perfusion imaging; Thrombolytic therapy

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; DIFFUSION WEIGHTED IMAGING; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PREDICTION; PRIORITY JOURNAL; RANKIN SCALE; REPERFUSION; FIBRINOLYTIC THERAPY; MIDDLE AGED; PREDICTIVE VALUE; SINGLE BLIND PROCEDURE; STROKE; TIME; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SINGLE-BLIND METHOD; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84922480152     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006082     Document Type: Article

References (18)

1. Baird AE, Lövblad KO, Dashe JF, Connor A, Burzynski C, Schlaug G, et al. Clinical correlations of diffusion and perfusion lesion volumes in acute ischemic stroke. Cerebrovasc Dis. 2000;10:441-448.
2. Cho KH, Kwon SU, Lee DH, Shim W, Choi C, Kim SJ, et al. Early infarct growth predicts long-term clinical outcome after thrombolysis. J Neurol Sci. 2012;316:99-103.
3. Derex L, Nighoghossian N, Hermier M, Adeleine P, Berthezène Y, Philippeau F, et al. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci. 2004;225:3-9.
4. Johnston KC, Barrett KM, Ding YH, Wagner DP; Acute Stroke Accurate Prediction Investigators. Clinical and imaging data at 5 days as a surrogate for 90-day outcome in ischemic stroke. Stroke. 2009;40:1332-1333.
5. Kimura K, Sakamoto Y, Iguchi Y, Shibazaki K. Serial changes in ischemic lesion volume and neurological recovery after t-PA therapy. J Neurol Sci. 2011;304:35-39.
6. Kruetzelmann A, Köhrmann M, Sobesky J, Cheng B, Rosenkranz M, Röther J, et al. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke. Stroke. 2011;42:1251-1254.
7. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462-469.
8. Chalela JA, Ezzeddine M, Latour L, Warach S. Reversal of perfusion and diffusion abnormalities after intravenous thrombolysis for a lacunar infarction. J Neuroimaging. 2003;13:152-154.
9. Labeyrie MA, Turc G, Hess A, Hervo P, Mas JL, Meder JF, et al. Diffusion lesion reversal after thrombolysis: a MR correlate of early neurological improvement. Stroke. 2012;43:2986-2991.
10. Merino JG, Latour LL, Todd JW, Luby M, Schellinger PD, Kang DW, et al. Lesion volume change after treatment with tissue plasminogen activator can discriminate clinical responders from nonresponders. Stroke. 2007;38:2919-2923.
11. Campbell BC, Tu HT, Christensen S, Desmond PM, Levi CR, Bladin CF, et al. Assessing response to stroke thrombolysis: validation of 24-hour multimodal magnetic resonance imaging. Arch Neurol. 2012;69:46-50.
12. Merino JG, Latour LL, An L, Hsia AW, Kang DW, Warach S. Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity. Stroke. 2008;39:2148-2150.
13. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
14. Lansberg MG, Thijs VN, Hamilton S, Schlaug G, Bammer R, Kemp S, et al; DEFUSE Investigators. Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke. 2007;38:1826-1830.
15. Goldstein LB. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The DEFUSE study. Curr Atheroscler Rep. 2007;9:258-259.
16. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
17. Freeman JW, Luby M, Merino JG, Latour LL, Auh S, Song SS, et al. Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction. Stroke. 2013;44:1629-1634.
18. Luby M, Bykowski JL, Schellinger PD, Merino JG, Warach S. Intra-and interrater reliability of ischemic lesion volume measurements on diffusion-weighted, mean transit time and fluid-attenuated inversion recovery MRI. Stroke. 2006;37:2951-2956.